Iacob SA, Iacob DG, Jugulete G. Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations. Front Pharmacol. 2017;8:831. https://doi.org/10.3389/fphar.2017.00831.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Miguel BR, Montejano R, Stella-Ascariz N, Arribas JR. New strategies of ARV: the road to simplification. Curr HIV/AIDS Rep. 2018;15(1):11–9. https://doi.org/10.1007/s11904-018-0371-6.

Article  Google Scholar 

Khalili H, Rohani R, Seyedalinaghi S, Hajiabdolbaghi M, Dashti-Khavidaki S, Talasaz AH. Adherence to Antiretroviral therapy among Iranian HIV/AIDS Patients. Curr Clin Pharmacol. 2012;7:111–5. https://doi.org/10.2174/157488412800228910.

Article  CAS  PubMed  Google Scholar 

Moradi A, Alavi SM, Fahim far N, Haghighizadeh MH, Mirzaei B. Study of determinants of adherence to antiretroviral treatment among HIV Patients covered by Ahwaz Jundishapur University of Medical Sciences. Int J Med Res Health Sci. 2016;5:477–84.

Google Scholar 

Bojdy A, Arian M, Najafi M, Mottaghi M. Adherence to antiretroviral therapy and its determinants in HIV patients in Mashhad, IRAN, a prospective study. Rev Clin Med. 2018;7:157–62.

Google Scholar 

Morowatisharifabad MA, Movahed E, Farokhzadian J, Nikooie R, Hosseinzadeh M, Askarishahi M, et al. Antiretroviral therapy adherence and its determinant factors among people living with HIV/AIDS: a case study in Iran. BMC Res Notes. 2019;12:162. https://doi.org/10.1186/s13104-019-42045.

Article  PubMed  PubMed Central  Google Scholar 

Chastain D, Badowski M, Huesgen E, Pandit NS, Pallotta A, Michienzi S. Optimizing antiretroviral therapy in treatment-experienced patients living with HIV: a critical review of switch and simplification strategies. An opinion of the HIV practice and research network of the American College of clinical pharmacy. J Int Assoc Provid AIDS Care. 2019;18:2325958219867325. https://doi.org/10.1177/2325958219867325.

Article  PubMed  Google Scholar 

Corado KC, Caplan MR, Daar ES. Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy. Drug Des Devel Ther. 2018;12:3731–40. https://doi.org/10.2147/DDDT.S140767.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Badowski M, Pérez SE, Silva D, Lee A. Two’s a company, three’s a crowd: a review of initiating or switching to a two-drug antiretroviral regimen in treatment-naïve and treatment-experienced patients living with HIV-1. Infect Dis Ther. 2020;9:185–208. https://doi.org/10.1007/s40121-020-00290-w.

Article  PubMed  PubMed Central  Google Scholar 

Waters L, Church H. Two drug regimens for HIV. Curr Opin Infect Dis. 2020;33:28–33. https://doi.org/10.1097/QCO.0000000000000615.

Article  PubMed  Google Scholar 

Brooks KM, Sherman EM, Egelund EF, Brotherton A, Durham S, Badowski ME, et al. Integrase inhibitors: after 10 years of experience, is the best yet to come? Pharmacotherapy. 2019;39:576–98. https://doi.org/10.1002/phar.2246.

Article  PubMed  Google Scholar 

Wandeler G, Buzzi M, Anderegg N, Sculier D, Béguelin C, Egger M, et al. Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis. F1000Res. 2018;7:1359. https://doi.org/10.12688/f1000research.15995.2.

Article  PubMed  Google Scholar 

Punekar YS, Parks D, Joshi M, Kaur S, Evitt L, Chounta, et al. Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence. HIV Med. 2021;22:423–33. https://doi.org/10.1111/hiv.13050.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cahn P, Sierra Madero J, Arribas JR, Antinori A, Ortiz R, Clarke AE, et al. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection. AIDS. 2022;36:39–48. https://doi.org/10.1097/QAD.0000000000003070.

Article  CAS  PubMed  Google Scholar 

Maggiolo F, Gulminetti R, Pagnucco L, Digaetano M, Cervo A, Valenti D, et al. Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. BMC Infect Dis. 2022;22:782. https://doi.org/10.1186/s12879-022-07769-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Girard PM, Cabié A, Michelet C, et al. A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients. J Anti microb Chemother. 2009;64:126–34.

Article  CAS  Google Scholar 

Pinola M, Lazzarin A, Antinori A, et al. Lopinavir/ ritonavir? tenofovir dual therapy versus lopinavir/ ritonavir-based triple therapy in HIV-infected antiretroviral naïve subjects: the Kalead Study. J Antivir Antiretrovir. 2010;2:56–62. https://doi.org/10.4172/jaa.1000024.

Article  CAS  Google Scholar 

Wassner C, Bradley N, Lee Y. A review and clinical understanding of tenofovir: tenofovir disoproxil fumarate versus tenofovir alafenamide. J Int Assoc Provid AIDS Care. 2020;19:2325958220919231. https://doi.org/10.1177/2325958220919231.

Article  PubMed  PubMed Central  Google Scholar 

Pilkington V, Hughes SL, Pepperrell T, McCann K, Gotham D, Pozniak AL, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials. AIDS. 2020;34:2259–68. https://doi.org/10.1097/QAD.0000000000002699.

Article  PubMed  Google Scholar 

Emamzadeh-Fard S, Fard SE. Author, Paydary K, Adherence to anti-retroviral therapy and its determinants in HIV/AIDS patients: a review. Infect Disord Drug Targets. 2012;12:346–56. https://doi.org/10.2174/187152612804142251.

Article  CAS  PubMed  Google Scholar 

https://eacs.sanfordguide.com/art/virological-failure. Accessed 8 Jan 2023.

Sculier D, Wandeler G, Yerly S, Marinosci A, Stoeckle M, Bernasconi E, et al. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL’HIV trial. PLoS Med. 2020;17:e1003421. https://doi.org/10.1371/journal.pmed.1003421.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ward D, Ramgopal M, Riedel DJ, Garris C, Dhir S, Waller J, et al. Real-world experience with dolutegravir-based two-drug regimens. AIDS Res Treat. 2020;7:5923256. https://doi.org/10.1155/2020/5923256.

Article  CAS  Google Scholar 

Atta MG, De Seigneux S, Lucas GM. Clinical pharmacology in HIV therapy. Clin J Am Soc Nephrol. 2019;14:435–44. https://doi.org/10.2215/CJN.02240218.

Article  CAS  PubMed  Google Scholar 

https://programme.aids2022.org/PAGMaterial/PPT/3733_4919/IAS_ADVANCE_W192POSTER_2022_AQ13JUL22.pdf. Accessed 10 Jan 2023.

Mallon PW, Brunet L, Hsu RK, Fusco JS, Mounzer KC, Prajapati G, et al. Weight gain before and after switch from TDF to TAF in a U.S. cohort study. J Int AIDS Soc. 2021;24:e25702. https://doi.org/10.1002/jia2.25702.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Surial B, Mugglin C, Calmy A, Cavassini M, Günthard HF, Stöckle M, et al. Swiss HIV cohort study. Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: a cohort study. Ann Intern Med. 2021;174:758–67. https://doi.org/10.7326/M20-4853.

Article  PubMed  Google Scholar 

Darnell J, Jain S, Sun X, Qin H, Reynolds T, Karris MY, et al. Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen. Medicine (Baltimore). 2021;100:e27047. https://doi.org/10.1097/MD.0000000000027047.

Article  CAS  PubMed  Google Scholar 

Kanters S, Renaud F, Rangaraj A, Zhang K, Limbrick-Oldfield E, Hughes M, et al. Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis. E Clin Med. 2022;48:101412. https://doi.org/10.1016/j.eclinm.2022.101412.

Article  Google Scholar 

Emond B, Rossi C, Rogers R, Lefebvre P, Lafeuille MH, Donga P. Real-world analysis of weight gain and body mass index increase among patients with HIV-1 using antiretroviral regimen containing tenofovir alafenamide, tenofovir disoproxil fumarate, or neither in the United States. J Health Econ Outcomes Res. 2022;9:39–49. https://doi.org/10.36469/jheor.2022.31825.

Article  PubMed  PubMed Central  Google Scholar 

Wood BR, Huhn GD. Excess weight gain with integrase inhibitors and tenofovir alafenamide: what is the mechanism and does it matter? Open Forum Infect Dis. 2021;8:ofab542.

Article  PubMed  PubMed Central  Google Scholar 

Petrakis V, Panagopoulos P, Papachristou S, Papanas N, Terzi I, Trypsianis G, et al. Tenofovir alafenamide fumarate therapy for HIV treatment: cardiometabolic and renal safety. AIDS Res Hum Retroviruses. 2020;36:697–702. https://doi.org/10.1089/AID.2019.0280.10.1093/ofid/ofab542.

Article  CAS  PubMed  Google Scholar